Table 2.
Immunophenotypic comparison between HCL, HCL-v and SMZL
| Antigen | HCL | HCL-v | SMZL |
|---|---|---|---|
| CD19 | 99% (168/169) | 100% (35/35) | 100% (9/9) |
| 2% (4/169)@ | 3% (1/35)@ | ||
| 0.6% (1/169)¶ | 3% (1/35)¶ | ||
|
| |||
| CD20 | 99% (168/169) | 100% (35/35) | 89% (8/9) |
| 88% (148/169)@ | 94% (33/35)@ | ||
|
| |||
| CD22 | 100% (169/169) | 100% (35/35) | 100% (9/9) |
| 96% (162/169)@ | 97% (34/35)@ | 11% (1/9)@ | |
|
| |||
| CD11c | 99% (167/169) | 100% (35/35) | 67% (6/9)¶ |
| 91% (154/169)@ | 63% (22/35)@ | ||
|
| |||
| CD25 | 100% (169/169) | 0% (0/35) | 22% (2/9)¶ |
| 98% (165/169)@ | 0% (0/9)@ | ||
|
| |||
| CD103 | 100% (169/169) | 100% (35/35) | 0% (0/9) |
| 3% (1/35)* | |||
|
| |||
| CD123 | 100% (114/114)@ | 40% (8/20)¶ | 25% (1/4)¶ |
|
| |||
| CD5 | 2% (4/169) | 3% (1/35) | 22% (2/9)¶ |
|
| |||
| CD10 | 12% (21/169) | 3% (1/35) | 0% (0/8) |
|
| |||
| CD23 | 21% (36/169)* | 14% (5/35)* | 38% (3/8) |
|
| |||
| CD38 | 14% (8/58) | 0% (0/35) | 22% (2/9) |
|
| |||
| CD2 | 2% (3/169) | 9% (3/35) | ND |
|
| |||
| CD4 | 0.5% (1/169) | 0% (0/35) | ND |
|
| |||
| CD13 | 0.5% (1/169) | 3% (1/35) | ND |
|
| |||
| Kappa | 48% (81/169) | 49% (17/35) | 67% (6/9) |
|
| |||
| Lambda | 48% (82/169) | 40% (14/35) | 33% (3/9) |
|
| |||
| Monophasic# | 4% (6/169) | 11% (4/35) | ND |
@
Bright expression;
¶
Dim expression;
*
Heterogeneous/partial expression
#
Monophasic without apparent surface light chain expression
ND: Not Done, HCL: Hairy cell leukemia, HCL-v: Hairy cell leukemia-variant, SMZL: splenic marginal zone lymphoma